An interventional study of TENS in Fibromyalgia, sponsored by Kathleen Sluka. Completed at 2 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-31.
Sponsored by Kathleen Sluka · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 55th largest by enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2013, is one of 167 with no phase, and was the 180th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 13 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
Kathleen Sluka is the lead sponsor of 3 studies on the registry; none are open to participants now.
Kathleen Sluka has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06066853Spaulding Rehabilitation HospitalMDMA-assisted Therapy for Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pain associated with fibromyalgia interferes with daily function, work, and social activities resulting in a decreased quality of life. People with fibromyalgia also have a significant amount of fatigue and a fear of movement. People with fibromyalgia show enhanced excitability of pain neurons in the central nervous system and reduced pain inhibition. Therefore, one of the main treatments for patients with fibromyalgia must focus on pain relief to allow the person to function more independently both at home and at work. Transcutaneous electrical nerve stimulation is used by health professionals to deliver electrical stimulation through the skin for pain control. Basic science studies, from the PI's laboratory show that TENS activates descending pain inhibitory pathways to inhibit excitability of pain neurons. Thus the ideal patient population for the treatment of TENS would be one in which there is enhanced central excitability and reduced inhibition; fibromyalgia is such a condition.
Hypothesis: The investigators hypothesize that application of Transcutaneous Electrical Nerve Stimulation (TENS) to patients with fibromyalgia will reduce resting and movement-related pain and reduce central excitability by restoring diffuse noxious inhibitory controls (DNIC), and that this decrease in pain and/or central excitability will reduce fatigue and fear of movement, thereby improving function and quality of life
This is a phase II randomized, double-blind, placebo controlled multi-center clinical trial involving a device, Transcutaneous Electrical Nerve Stimulation (TENS). TENS is a non-pharmacological agent which delivers electrical stimulation by a battery operated device via electrodes placed on the skin. TENS is considered to be a safe, inexpensive and non-invasive modality used to treat a variety of acute and chronic pain conditions. The initial phase of the study will randomly allocate subjects to receive active TENS, placebo TENS or standard care (No TENS). After participating in the 1 month random assignment, all subjects will receive active TENS for 1 month. The subjects will make 4 visits to the clinic approximately 2 to 3 1/2 hours each visit. Visits will entail questionnaires, functional tasks, accelerometry, TENS, pain and fatigue assessments.
Study Aims:
Aim #1: The primary aim of the study is to test the effectiveness of repeated TENS use on movement-related pain in people with fibromyalgia with random assignment to three treatments: standard care, placebo TENS and active Aim #2: A secondary aim will test if pain reduction by TENs results in a concomitant decrease in fatigue and fear of movement, and an increase in function and quality of life. Outcome measures will include physical function by directly assessing daily activity with an accelerometer, as well as performing specific functional tasks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
Device: TENS
This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
Device: TENS
Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
TENS Parameters: Active TENS and Placebo TENS * TENS Frequency - 2-125 Hz * TENS Pulse Width - 200 µs * TENS Intensity - Maximal tolerable intensity * Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes. * Administration - Daily * TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region. Placebo TENS Unit Active TENS unit No TENS - Standard Care
Also known as: Empi Select Unit
Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test
Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS
Pain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test
Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Resting Pain (0-10 Low to High Scale)
Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)
Fatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test
Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Fatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand
Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Resting Fatigue Rating (0-10 Low to High Scale)
Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Fibromyalgia Impact Questionnaire Revised
Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Fibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)
numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Brief Pain Inventory - Interference (0-10 Low to High Scale)
Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Brief Pain Inventory, Intensity (0-10 Low to High Scale)
Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Tampa Scale of Kinesiophobia (17 to 68 Low to High)
Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Short Form Survey 36; Mental Component Score (T Score Mean of 50)
Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Short Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health
Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Six Minute Walk Test
6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Five Time Sit to Stand Test Rate Per 10 Seconds
Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Moderate Vigorous Physical Activity Minutes Per Day
Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
| Milestone | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Started | 103 | 99 | 99 |
| Completed | 76 | 68 | 94 |
| Not completed | 27 | 31 | 5 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 15 | 11 | 4 |
| Withdrew: Minimum dose not met | 10 | 16 | 0 |
| Withdrew: Given wrong unit (placebo) | 1 | 0 | 0 |
| Withdrew: Excluded for prior tens | 0 | 1 | 0 |
| Withdrew: Researcher termination of participant | 0 | 1 | 1 |
Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.8 (-2.3 to -1.2) | -0.8 (-1.4 to -0.2) | 0.00 (-0.5 to 0.6) |
| Change at 8 weeks | -2.0 (-2.8 to -1.3) | -1.9 (-2.7 to -1.2) | -1.9 (-2.6 to -1.2) |
Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.6 (-2.30 to -1.0) | -0.3 (-1.0 to 0.3) | 0.2 (-0.4 to 0.9) |
| Change at 8 weeks | -1.9 (-2.6 to -1.1) | -1.4 (-2.2 to -0.7) | -1.3 (-2.1 to -0.6) |
Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.9 (-2.5 to -1.4) | -0.7 (-1.3 to -0.1) | -0.5 (-1.1 to 0.00) |
| Change at 8 weeks | -2.2 (-2.9 to -1.6) | -1.9 (-2.6 to -1.2) | -2.2 (-2.8 to -1.5) |
Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.5 (-2.2 to -0.8) | -0.1 (-0.9 to 0.7) | 0.4 (-0.3 to 1.1) |
| Change at 8 weeks | -1.3 (-2.0 to -0.6) | -0.9 (-1.7 to -0.2) | -0.9 (-1.7 to -0.2) |
Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.2 (-1.9 to -0.5) | -0.0 (-0.8 to 0.7) | 0.8 (0.1 to 1.5) |
| Change at 8 weeks | -1.1 (-1.9 to -0.4) | -0.8 (-1.6 to -0.1) | -0.6 (-1.4 to 0.1) |
Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.9 (-2.6 to -1.2) | -0.8 (-1.5 to -0.04) | -0.4 (-1.0 to 0.4) |
| Change at 8 weeks | -2.1 (-2.9 to -1.4) | -1.6 (-2.4 to -0.8) | -1.8 (-2.6 to -1.1) |
Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -8.5 (-12.9 to 4.0) | -3.4 (-6.5 to 0.3) | -1.39 (-4.4 to 1.6) |
| Change at 8 weeks | -9.6 (-13.8 to 5.4) | -11.1 (-15.2 to 7.0) | -10.7 (-14.8 to -6.6) |
numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1.3 (-1.8 to -0.7) | -0.4 (-0.9 to -0.2) | -0.1 (-0.6 to 0.4) |
| Change at 8 weeks | -1.4 (-2.0 to -0.8) | -1.2 (-1.7 to -0.6) | -1.4 (-1.9 to -0.8) |
Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -0.9 (-1.4 to -0.5) | -0.3 (-0.7 to 0.2) | -0.3 (-0.7 to 0.2) |
| Change at 8 weeks | -1.1 (-1.6 to -0.6) | -0.9 (-1.4 to -0.3) | -1.2 (-1.7 to -0.7) |
Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -0.8 (-1.1 to -0.4) | -0.3 (-0.6 to 0.1) | 0.15 (-0.2 to 0.5) |
| Change at 8 weeks | -1.0 (-1.4 to -0.6) | -0.9 (-1.3 to -0.5) | -0.9 (-1.2 to -0.5) |
Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| units on a scale | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -0.7 (-2.0 to 0.6) | -0.3 (-1.7 to 1.0) | -0.2 (-1.4 to 1.1) |
| Change at 8 weeks | -0.3 (-1.6 to 1.1) | -2.3 (-3.7 to -0.9) | -3.3 (-4.6 to -2.0) |
Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life
| T-Score | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | 2.3 (0.2 to 4.4) | 1.2 (-0.9 to 3.4) | -0.04 (-2.1 to 2.0) |
| Change at 8 weeks | 2.1 (-0.2 to 4.4) | 3.6 (1.3 to 6.0) | 2.8 (0.6 to 5.0) |
Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .
| T-Score | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | 2.4 (1.0 to 3.7) | 1.2 (-0.2 to 2.5) | 1.4 (0.1 to 2.6) |
| Change at 8 weeks | 3.5 (2.0 to 5.1) | 3.2 (1.6 to 4.8) | 4.4 (2.9 to 5.9) |
6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Feet | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -1 (-55 to 54) | -20 (-75 to 36) | -42.1 (-95 to 11) |
| Change at 8 weeks | 15 (-42 to 71) | 16 (-41 to 74) | -2 (-57 to 53) |
Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| sit-to-stand repetitions/10 seconds | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | 0.6 (0.3 to 1.0) | 0.4 (0.0 to 0.7) | 0.1 (-0.3 to 0.4) |
| Change at 8 weeks | 0.6 (0.2 to 1.0) | 0.8 (0.4 to 1.3) | 0.6 (0.1 to 1.0) |
Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
| Minutes per day | Active TENS | Placebo TENS | No TENS (Standard Care) |
|---|---|---|---|
| Change at 4 weeks | -9.4 (-27.8 to 13.5) | 2.5 (-18.6 to 29.1) | -14.1 (-29.5 to 4.7) |
| Change at 8 weeks | -6.8 (-27.2 to 19.3) | -0.3 (-22.3 to 27.9) | -17.0 (-33.9 to 4.1) |
Collected over Visit 1 to Visit 4, 9 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active TENS | 0/103 (0%) | 0/103 (0%) | 12/103 (11.7%) |
| Placebo TENS | 0/99 (0%) | 1/99 (1%) | 10/99 (10.1%) |
| No TENS (Standard Care) | 0/99 (0%) | 2/99 (2%) | 15/99 (15.2%) |
| Pre-Randomization | 0/352 (0%) | 1/352 (0.3%) | 0/352 (0%) |
| Event | Active TENS | Placebo TENS | No TENS (Standard Care) | Pre-Randomization |
|---|---|---|---|---|
| Chest painCardiac disorders | 0/103 | 1/99 | 0/99 | 0/352 |
| Dehydration and gastrointestinal painGastrointestinal disorders | 0/103 | 0/99 | 1/99 | 0/352 |
| DepressionPsychiatric disorders | 0/103 | 0/99 | 1/99 | 0/352 |
| Chest painCardiac disorders | 0/103 | 0/99 | 0/99 | 1/352 |
| Event | Active TENS | Placebo TENS | No TENS (Standard Care) | Pre-Randomization |
|---|---|---|---|---|
| Pain with testingNervous system disorders | 12/103 | 10/99 | 15/99 | 0/352 |
| Upper RespiratoryRespiratory, thoracic and mediastinal disorders | 7/103 | 7/99 | 3/99 | 0/352 |
| Upper Respiratory InfectionRespiratory, thoracic and mediastinal disorders | 7/103 | 7/99 | 3/99 | 0/352 |
| Skin Irritation with ElectrodesSkin and subcutaneous tissue disorders | 6/103 | 2/99 | 0/99 | 0/352 |
| Pain with TENS; At home, unspecifiedGeneral disorders | 4/103 | 4/99 | 3/99 | 0/352 |
| Common ColdRespiratory, thoracic and mediastinal disorders | 3/103 | 4/99 | 2/99 | 0/352 |
| FallGeneral disorders | 4/103 | 3/99 | 2/99 | 0/352 |
| Skin Irritation from actigraph bandSkin and subcutaneous tissue disorders | 2/103 | 3/99 | 1/99 | 0/352 |
| Headache or MigraineGeneral disorders | 3/103 | 3/99 | 1/99 | 0/352 |
| Dental ProceduresGeneral disorders | 2/103 | 2/99 | 3/99 | 0/352 |
| Age, Categorical(Participants) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 97 | 93 | 95 | 285 |
| >=65 years | 6 | 6 | 4 | 16 |
| Age, Continuous(Years) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| Mean | 44.7 ± 14.3 | 47.2 ± 12.6 | 48.6 ± 11.8 | 46.8 ± 12.9 |
| Sex: Female, Male(Participants) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| Female | 103 | 99 | 99 | 301 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 5 | 15 |
| Not Hispanic or Latino | 96 | 92 | 88 | 276 |
| Unknown or Not Reported | 2 | 2 | 6 | 10 |
| Race (NIH/OMB)(Participants) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 0 | 3 |
| Asian | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 5 | 0 | 0 | 5 |
| Black or African American | 0 | 5 | 3 | 8 |
| White | 90 | 87 | 85 | 262 |
| More than one race | 4 | 3 | 5 | 12 |
| Unknown or Not Reported | 1 | 1 | 5 | 7 |
| Region of Enrollment(participants) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| United States | 103 | 99 | 99 | 301 |
| Pain with movement six minute walk test(0 to 10 low to high scale) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| Mean | 6.5 ± 1.9 | 6.2 ± 1.9 | 6.4 ± 1.9 | 6.4 ± 1.9 |
| Pain with movement five time sit to stand(0 to 10 low to high scale) | Active TENS | Placebo TENS | no TENS (Standard Care) | Total |
|---|---|---|---|---|
| Mean | 5.8 ± 2.4 | 5.5 ± 2.2 | 5.6 ± 2.2 | 5.6 ± 2.2 |
10 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — By publication
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be made available by publication by April 2019 and for one year after closeout of the study and upon request with a proposed study protocol for 5 years.
Ran from Sep 2013 to primary completion in Apr 2018, 54 months.
Results were first posted in Oct 2019, 1 year 6 months after primary completion.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 54 months is above that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.